Clinical Efficacy Of Liraglutide In Obese Patients With Type 2 Diabetes Mellitus

Objective: The study was to investigate the effect of Liraglutide on the related indexes in the diagnosis of obese type 2 diabetes mellitus,in order to provide clinical evidence for the application of GLP-1 receptor agonists in those people with T2 DM.Methods: From April 2016 to December 2017,a total of 40 obese patients with type 2 diabetes who were treated with metformin hydrochloride enteric-coated tablets for over 3 months an whose blood glucose control was not well controlled were selected from the inpatient and outpatient department of endocrinology in the Affiliated Hospital of Guilin Medical College.According to the method of random arrangement,all of the 40 obese persons were arranged into 2 groups,and the 2 groups were the control group and the observation group.The control group(n=20)was given the basic oral medicine and insulin glargine.The observation group(n=20)were treated with basic oral medicine and Liraglutide injection.The basic oral medicine was the metformin hydrochloride enteric-coated tablets.To compare these changes of relative targets between the 2 groups before and after using medicine,and record the adverse drug reactions during the treatment,to valuate the clinical effect of the 2 groups.Results: Followed up for 12 weeks,the body weight,waistline,waist-to-hip ratio,fasting blood glucose,glycosylated hemoglobin,2 hours postprandial blood glucose,triglyceride,total cholesterol,low density lipoprotein cholesterol of the total 40 patients were measured lower than before(P<0.05).The standards of high density lipoprotein cholesterol and fasting C-peptide were higher than before,and the difference was statistically significant.The HOMA-IR of control group was higher than before,and the HOMA-IR of observation group was lower than before(P<0.05).9 patients in the control group developed hypoglycemia during the treatment and no hypoglycemia appeared in the observation group.The study proved that both of the two treatments were safe and effective,but the changes of the indexes in the observation group were more significant than those in the control group,and the curative effect was enormously better than that in the control group.The treatment of observation group also improved the islet cell function and the insulin resistance,and the incidence of hypoglycemia was low.Conclusions: The combined use of oral hypoglycemic drugs and Liraglutide can achieve good results in reducing body mass and stable blood glucose,regulating blood lipid and improving islet function after the treament followed up for 12 weeks in clinical treatment,and the therapeutic effect was better than the treatment of basic oral hypoglycemic drugs combined with insulin glargine.As a new hypoglycemic medicine,Liraglutide can effectively improve the function of islet cells,and it also can lose weight and reduce the risk of hypoglycemia.It is worth popularizing in clinical treatment.